|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF232 |
Gene summary for ZNF232 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF232 | Gene ID | 7775 |
| Gene name | zinc finger protein 232 | |
| Gene Alias | ZSCAN11 | |
| Cytomap | 17p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | I3L4J6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7775 | ZNF232 | LZE4T | Human | Esophagus | ESCC | 8.11e-06 | 1.51e-01 | 0.0811 |
| 7775 | ZNF232 | LZE24T | Human | Esophagus | ESCC | 1.84e-08 | 2.93e-01 | 0.0596 |
| 7775 | ZNF232 | P2T-E | Human | Esophagus | ESCC | 1.16e-17 | 3.19e-01 | 0.1177 |
| 7775 | ZNF232 | P4T-E | Human | Esophagus | ESCC | 1.25e-13 | 3.40e-01 | 0.1323 |
| 7775 | ZNF232 | P8T-E | Human | Esophagus | ESCC | 1.94e-05 | 1.59e-01 | 0.0889 |
| 7775 | ZNF232 | P10T-E | Human | Esophagus | ESCC | 6.27e-10 | 2.37e-01 | 0.116 |
| 7775 | ZNF232 | P11T-E | Human | Esophagus | ESCC | 5.03e-03 | 1.66e-01 | 0.1426 |
| 7775 | ZNF232 | P12T-E | Human | Esophagus | ESCC | 1.00e-12 | 2.66e-01 | 0.1122 |
| 7775 | ZNF232 | P16T-E | Human | Esophagus | ESCC | 1.05e-18 | 3.57e-01 | 0.1153 |
| 7775 | ZNF232 | P20T-E | Human | Esophagus | ESCC | 7.33e-03 | 1.54e-01 | 0.1124 |
| 7775 | ZNF232 | P21T-E | Human | Esophagus | ESCC | 8.52e-05 | 1.42e-01 | 0.1617 |
| 7775 | ZNF232 | P22T-E | Human | Esophagus | ESCC | 1.46e-07 | 1.62e-01 | 0.1236 |
| 7775 | ZNF232 | P23T-E | Human | Esophagus | ESCC | 5.68e-09 | 2.03e-01 | 0.108 |
| 7775 | ZNF232 | P24T-E | Human | Esophagus | ESCC | 1.26e-02 | 1.08e-01 | 0.1287 |
| 7775 | ZNF232 | P26T-E | Human | Esophagus | ESCC | 4.64e-04 | 1.16e-01 | 0.1276 |
| 7775 | ZNF232 | P27T-E | Human | Esophagus | ESCC | 3.27e-09 | 2.17e-01 | 0.1055 |
| 7775 | ZNF232 | P32T-E | Human | Esophagus | ESCC | 9.15e-05 | 1.12e-01 | 0.1666 |
| 7775 | ZNF232 | P36T-E | Human | Esophagus | ESCC | 3.10e-05 | 1.57e-01 | 0.1187 |
| 7775 | ZNF232 | P37T-E | Human | Esophagus | ESCC | 7.31e-05 | 9.67e-02 | 0.1371 |
| 7775 | ZNF232 | P42T-E | Human | Esophagus | ESCC | 2.26e-04 | 1.74e-01 | 0.1175 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF232 | SNV | Missense_Mutation | c.1136N>T | p.Arg379Met | p.R379M | Q9UNY5 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF232 | SNV | Missense_Mutation | novel | c.45N>A | p.Ser15Arg | p.S15R | Q9UNY5 | protein_coding | tolerated_low_confidence(0.06) | benign(0.021) | TCGA-BH-A42V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF232 | SNV | Missense_Mutation | c.1118N>C | p.His373Pro | p.H373P | Q9UNY5 | protein_coding | tolerated(0.08) | benign(0.065) | TCGA-E2-A1IL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ZNF232 | SNV | Missense_Mutation | rs766019408 | c.373N>A | p.Glu125Lys | p.E125K | Q9UNY5 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| ZNF232 | insertion | Frame_Shift_Ins | novel | c.287_288insTCTTCTTTCTTCCTTGACTTTTTTCCAGACTTTTTCTTGTCTCCTT | p.Ser98LeufsTer24 | p.S98Lfs*24 | Q9UNY5 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ZNF232 | insertion | Frame_Shift_Ins | novel | c.1258_1259insCTCTTGACCTCGTGATCTGCCCACCTCTGCCTCCCAAA | p.Cys420SerfsTer57 | p.C420Sfs*57 | Q9UNY5 | protein_coding | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| ZNF232 | SNV | Missense_Mutation | novel | c.1306N>A | p.Val436Ile | p.V436I | Q9UNY5 | protein_coding | tolerated(1) | benign(0.012) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF232 | SNV | Missense_Mutation | novel | c.936N>A | p.Phe312Leu | p.F312L | Q9UNY5 | protein_coding | deleterious(0.02) | benign(0.145) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF232 | SNV | Missense_Mutation | c.1175N>T | p.Cys392Phe | p.C392F | Q9UNY5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1M8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF232 | SNV | Missense_Mutation | novel | c.1250G>T | p.Cys417Phe | p.C417F | Q9UNY5 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |